Stock Titan provides an ultra-fast stock market news feed and multiple tools for traders and investors.

Biotech Radar: $APUS extends its rally, $AVBP falls after FURVENT misses, $JUNS starts Parkinson’s dosing and $OSTX reports survival data. Plus $CNXU, $SCYX.

Conexeu will present in New York and participate in Munich; it anticipates a 510(k) submission in early 2027, subject to regulatory review.

Conexeu Sciences (Nasdaq: CNXU), a preclinical-stage regenerative tissue platform company, highlights the emergence of a new medical aesthetics category focused on regenerative soft-tissue restoration, centered on the extracellular matrix (ECM). Independent research cited by Conexeu sizes the bioregenerative aesthetics segment at about $1.6 billion in 2025 with projected annual growth above 11%, within a broader regenerative aesthetics market estimated at $15.6 billion.Conexeu’s patented CXU™ ECM platform is designed as a multi-component collagen-ECM scaffold and underpins its lead device candidate, Ten-Minute Tissue™, a thermosensitive ECM material that gels in situ at body temperature in about ten minutes. The company recently completed the 12‑month P.R.O.O.F. preclinical phase, which met predefined objectives in small-volume facial and approximately 200cc-equivalent large-volume subcutaneous tissue models, while noting these volumes do not establish appropriate or safe human dosing. Conexeu holds a multi-jurisdictional patent estate spanning more than 40 jurisdictions and is pursuing a predicate-based U.S. regulatory strategy with an anticipated 510(k) submission in early 2027 for its initial indication, subject to regulatory review.

Conexeu (Nasdaq: CNXU) announced that Chief Medical Officer Dr. Brian Pilcher will give an industry presentation at the 2026 Controversies & Conversations in Laser & Cosmetic Surgery Symposium, held August 14–16, 2026. His August 15 talk, “Beyond Filling: An Extracellular Matrix Blueprint for Tissue Regeneration,” will focus on the role of the extracellular matrix (ECM) in tissue regeneration and regenerative aesthetics.The presentation aligns with Conexeu’s preclinical CXU™ ECM platform and its lead thermosensitive device candidate, Ten-Minute Tissue™, which is designed to support soft-tissue restoration and is supported by multiple peer‑reviewed preclinical studies.

YouTube video by Mugre Banda

Reno, Nevada--(Newsfile Corp. - May 21, 2026) - Conexeu Sciences Inc. (Nasdaq: CNXU) ("Conexeu" or the "Company"), a biotechnology company advancing tissue regeneration, announced it has officially commenced trading on the Nasdaq today under the ticker symbol "CNXU." The Company currently has 25,269,996 shares on an issued and outstanding basis and 35,238,222 shares on a fully diluted basis.To view an enhanced version of this graphic, please...

After a decade of Python development, Jay has gotten into the world of plant raising and believes that the answer to becoming better at PostgreSQL lies somewhere between the journey of more Pythonic…

Conexeu Sciences (NASDAQ:CNXU – Get Free Report) is one of 27 public companies in the “Surgical, Medical, And Dental Instruments And Supplies” industry, but how does it compare to its peers? We will compare Conexeu Sciences to related companies based on the strength of its valuation, profitability, earnings, risk, institutional ownership, analyst recommendations and dividends. [...]

YouTube video by Al Jazeera English

YouTube video by Al Jazeera English

Conexeu Sciences (NASDAQ: CNXU) stock is getting a lift as the company checks off key steps toward bringing its lead wound care device, CXU, into the clinic an

The Vancouver lab will center research, product development and commercialization for CXU regenerative tissue and B.R.E.A.S.T. after a June 23 ribbon-cutting.

Conexeu (Nasdaq:CNXU) expanded its leadership following its Nasdaq listing, increasing the Board from six to nine directors and updating committee roles.The company appointed Ana Bastiani-Posner, April Burke, and Andrew Costa to the Board, named Co-Founder David Bogart as Chief Commercial Officer, and added aesthetics expert Melinda Farina to its advisory board, supporting commercialization of its CXU™ platform and preclinical B.R.E.A.S.T.™ breast matrix.

Conexeu Sciences (Nasdaq: CNXU) reported progress in manufacturing scale up and standardized formulation for its lead CXU™ wound care device, working with a CDMO to generate materials for regulatory testing.The company targets a 510(k) FDA submission in Q1 2027, supported by ongoing manufacturing, packaging, sterilization, and documentation activities, informed by FDA Q-Submission feedback.

Nasdaq’s June 10 Closing Bell will feature Conexeu Sciences, marking its recent CNXU listing and 3D‑bioprinted breast matrix work with Wake Forest.